Galapagos NV (GXEA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Galapagos NV (GXEA) has a cash flow conversion efficiency ratio of -0.025x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-82.75 Million ≈ $-96.74 Million USD) by net assets (€3.25 Billion ≈ $3.80 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Galapagos NV fund operations to measure how many days the company can operate on defensive assets alone.
Galapagos NV - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Galapagos NV's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Galapagos NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galapagos NV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Stagwell Inc
NASDAQ:STGW
|
-0.035x |
|
Spartan Delta Corp
TO:SDE
|
0.139x |
|
FirstSun Capital Bancorp Common Stock
NASDAQ:FSUN
|
-0.011x |
|
Akzo Nobel India Limited
NSE:AKZOINDIA
|
-0.079x |
|
City Union Bank Limited
NSE:CUB
|
-0.382x |
|
Icade SA
PA:ICAD
|
0.064x |
|
Alembic Pharmaceuticals Limited
NSE:APLLTD
|
0.076x |
|
GS Engineering & Construction
KO:006360
|
0.011x |
Annual Cash Flow Conversion Efficiency for Galapagos NV (2016–2025)
The table below shows the annual cash flow conversion efficiency of Galapagos NV from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Galapagos NV (GXEA) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €3.24 Billion ≈ $3.78 Billion |
€-257.46 Million ≈ $-300.99 Million |
-0.080x | +27.98% |
| 2024-12-31 | €2.90 Billion ≈ $3.39 Billion |
€-320.03 Million ≈ $-374.14 Million |
-0.110x | +40.49% |
| 2023-12-31 | €2.80 Billion ≈ $3.27 Billion |
€-518.97 Million ≈ $-606.73 Million |
-0.186x | +6.32% |
| 2022-12-31 | €2.53 Billion ≈ $2.95 Billion |
€-500.54 Million ≈ $-585.19 Million |
-0.198x | -3.96% |
| 2021-12-31 | €2.64 Billion ≈ $3.09 Billion |
€-503.83 Million ≈ $-589.03 Million |
-0.191x | -19.10% |
| 2020-12-31 | €2.67 Billion ≈ $3.12 Billion |
€-427.34 Million ≈ $-499.60 Million |
-0.160x | -114.34% |
| 2019-12-31 | €2.88 Billion ≈ $3.36 Billion |
€3.21 Billion ≈ $3.75 Billion |
1.116x | +1050.99% |
| 2018-12-31 | €1.21 Billion ≈ $1.42 Billion |
€-142.47 Million ≈ $-166.56 Million |
-0.117x | +19.24% |
| 2017-12-31 | €1.01 Billion ≈ $1.18 Billion |
€-147.03 Million ≈ $-171.89 Million |
-0.145x | -146.04% |
| 2016-12-31 | €758.70 Million ≈ $887.00 Million |
€239.40 Million ≈ $279.89 Million |
0.316x | -- |
About Galapagos NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in… Read more